EGFR and nasopharyngeal carcinoma: Several studies have indicated that treatment with CTX or NTZ enhances the efficacy of chemoradiotherapy for locoregionally advanced NPC.11, 12, 13, 14, 15 However, the antitumor activity of anti‐EGFR mAbs for RM‐NPC has rarely been reported.16, 17 The aim of the present study was to evaluate the antitumor efficacy and safety of anti‐EGFR mAbs (CTX or NTZ) plus palliative chemotherapy as a first‐line treatment for RM‐NPC.